HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever enters tech partnership

This article was originally published in The Rose Sheet

Executive Summary

Dove marketer has entered into a five-year partnership with Silicon Valley-based Ampere Life Sciences to access the firm's Digital Biology technology platform and secure exclusive rights for the development of innovative consumer products, U.K. firm announces Sept. 16. Unilever and Ampere scientists will work together on "the core biology of aging" for a "range of benefit areas of interest to Unilever," company says. Unilever Chief R&D Officer Genevieve Berger touts firms' "commitment to develop superior products across a number of categories and exclusivity that will potentially give us competitive advantage in the marketplace." Deal is in line with Unilever's "open innovation" approach, and such efforts will help the company meet consumer demand for healthy living as the market for aging products increases, firm notes. Though terms of the deal were not disclosed, work will begin immediately, the companies say. Unilever recently announced an undisclosed investment in Solazyme, a firm that produces renewable oil and bioproducts from algae that can be used as a substitute for petroleum and plant oils in personal-care products (1"The Rose Sheet" Sept. 20, 1010)

You may also be interested in...



Could Unilever Investment In Microalgae Solve Firm's Palm Oil Problems?

Unilever is reasserting its commitment to environmental sustainability with an undisclosed investment in Solazyme, the same company that is helping the U.S. Navy to reach its renewable fuel goals

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel